0001193125-26-182251.txt : 20260427 0001193125-26-182251.hdr.sgml : 20260427 20260427163832 ACCESSION NUMBER: 0001193125-26-182251 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260427 FILED AS OF DATE: 20260427 DATE AS OF CHANGE: 20260427 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rosenberg Ellen CENTRAL INDEX KEY: 0001666380 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 26901611 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 ownership.xml 4 X0609 4 2026-04-27 true 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001666380 Rosenberg Ellen false 47 HULFISH STREET PRINCETON NJ 08542 false true false false Chief Legal Officer false Common Stock 2026-04-27 4 D false 463898 14.50 D 0 D Common Stock 2026-04-27 4 D false 15000 14.50 D 0 I By Spouse Stock Options (right to buy) 10.04 2026-04-27 4 D false 93663 D 2029-01-02 Common Stock 93663 0 D Stock Options (right to buy) 9.55 2026-04-27 4 D false 107575 D 2030-01-02 Common Stock 107575 0 D Stock Options (right to buy) 12.11 2026-04-27 4 D false 134044 D 2032-01-03 Common Stock 134044 0 D Stock Options (right to buy) 11.93 2026-04-27 4 D false 138008 D 2033-01-03 Common Stock 138008 0 D Stock Options (right to buy) 14.24 2026-04-27 4 D false 108980 D 2034-01-02 Common Stock 108980 0 D Stock Options (right to buy) 9.41 2026-04-27 4 D false 203825 D 2035-01-03 Common Stock 203825 0 D The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 311,410 shares of Common Stock and 152,488 restricted stock units (which vested in full in connection with consummation of the Merger). The reported securities were disposed of in connection with the consummation of the Merger, which included 15,000 shares of Common Stock. In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. Each Option vested in full in connection with consummation of the Merger. /s/ Christian Formica, Attorney-in-Fact 2026-04-27